Nature Communications (Jan 2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- Hirokazu Taniguchi,
- Tadaaki Yamada,
- Rong Wang,
- Keiko Tanimura,
- Yuta Adachi,
- Akihiro Nishiyama,
- Azusa Tanimoto,
- Shinji Takeuchi,
- Luiz H. Araujo,
- Mariana Boroni,
- Akihiro Yoshimura,
- Shinsuke Shiotsu,
- Isao Matsumoto,
- Satoshi Watanabe,
- Toshiaki Kikuchi,
- Satoru Miura,
- Hiroshi Tanaka,
- Takeshi Kitazaki,
- Hiroyuki Yamaguchi,
- Hiroshi Mukae,
- Junji Uchino,
- Hisanori Uehara,
- Koichi Takayama,
- Seiji Yano
Affiliations
- Hirokazu Taniguchi
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Tadaaki Yamada
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Rong Wang
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Keiko Tanimura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Yuta Adachi
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Akihiro Nishiyama
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Azusa Tanimoto
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Shinji Takeuchi
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Luiz H. Araujo
- Division of Clinical Research, Brazilian National Cancer Institute
- Mariana Boroni
- Division of Experimental and Translational Research, Bioinformatics and Computational Biology Lab, Brazilian National Cancer Institute
- Akihiro Yoshimura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Shinsuke Shiotsu
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital
- Isao Matsumoto
- Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University
- Satoshi Watanabe
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences
- Toshiaki Kikuchi
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences
- Satoru Miura
- Department of Internal Medicine, Niigata Cancer Center Hospital
- Hiroshi Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital
- Takeshi Kitazaki
- Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital
- Hiroyuki Yamaguchi
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences
- Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences
- Junji Uchino
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Hisanori Uehara
- Department of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School
- Koichi Takayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Seiji Yano
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- DOI
- https://doi.org/10.1038/s41467-018-08074-0
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Resistance to the new generation EGFR-TKI, Osimertinib, can emerge in patients with EGFR-mutated lung cancer. Here, the authors show that AXL, which is activated by osimertinib, can promote the emergence of tolerant lung cancer cell thus conferring resistance to osimertinib and propose the combination of Osimertinib with AXL inhibitor as a potential therapeutic approach in such resistant cancers.
